PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17178769-0	2007	Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception.	Alfentanil	41-51	phosphoglycolate phosphatase	Mus musculus	55-69	
17178769-2	2007	The impact of P-gp-mediated efflux on the disposition and efficacy of the synthetic opioid alfentanil currently is unknown.	Alfentanil	91-101	phosphoglycolate phosphatase	Mus musculus	14-18	
17178769-5	2007	A pharmacokinetic-pharmacodynamic (PK-PD) model was fit to the data and used to assess the impact of P-gp on parameters associated with alfentanil disposition and action.	Alfentanil	136-146	phosphoglycolate phosphatase	Mus musculus	101-105	
17178769-11	2007	These results indicate that alfentanil is an in vivo P-gp substrate and are consistent with the hypothesis that P-gp-mediated efflux attenuates antinociception by reducing alfentanil K(p,brain,ss).	Alfentanil	28-38	phosphoglycolate phosphatase	Mus musculus	53-57	
17178769-11	2007	These results indicate that alfentanil is an in vivo P-gp substrate and are consistent with the hypothesis that P-gp-mediated efflux attenuates antinociception by reducing alfentanil K(p,brain,ss).	Alfentanil	28-38	phosphoglycolate phosphatase	Mus musculus	112-116